Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario

M. Kyr, K. Polaskova, Z. Kuttnerova, T. Merta, J. Neradil, J. Berkovcova, O. Horky, M. Jezova, R. Veselska, GL. Klement, D. Valik, J. Sterba,

. 2019 ; 9 (-) : 644. [pub] 20190717

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035847

Grantová podpora
NV16-34083A MZ0 CEP - Centrální evidence projektů
NV16-34083A MZ0 CEP - Centrální evidence projektů

Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without international collaboration. We therefore propose comparative patient series analysis in a real-life scenario. Methods: Open cohort observational study, comparative analysis. Seventy patients with high-risk solid tumors diagnosed between 2003 and 2015 and in whom the treatment was individualized either empirically or based on biomarkers were analyzed. The heterogeneity of the cohort and repeated measurements were advantageously utilized to increase effective sample size using appropriate statistical tools. Results: We demonstrated a beneficial effect of empirically given low-dose metronomic chemotherapy (HR 0.46 for relapses, p = 0.017) as well as various repurposed or targeted agents (HR 0.15 for deaths, p = 0.004) in a real-life scenario. However, targeted agents given on the basis of limited biological information were not beneficial. Conclusions: Comparative patient series analysis provides institutional-level evidence for treatment individualization in high-risk pediatric malignancies. Our findings emphasize the need for a comprehensive, multi omics assessment of the tumor and the host as well whenever molecularly driven targeted therapies are being considered. Low-dose metronomic chemotherapy or local control of the disease may be a more rational option in situations where targeted treatment cannot be justified by robust evidence and comprehensive biological information. "Targeted drugs" may be given empirically with a realistic benefit expectation when based on robust rationale.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035847
003      
CZ-PrNML
005      
20191011114927.0
007      
ta
008      
191007s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2019.00644 $2 doi
035    __
$a (PubMed)31380281
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kyr, Michal $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia.
245    10
$a Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario / $c M. Kyr, K. Polaskova, Z. Kuttnerova, T. Merta, J. Neradil, J. Berkovcova, O. Horky, M. Jezova, R. Veselska, GL. Klement, D. Valik, J. Sterba,
520    9_
$a Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without international collaboration. We therefore propose comparative patient series analysis in a real-life scenario. Methods: Open cohort observational study, comparative analysis. Seventy patients with high-risk solid tumors diagnosed between 2003 and 2015 and in whom the treatment was individualized either empirically or based on biomarkers were analyzed. The heterogeneity of the cohort and repeated measurements were advantageously utilized to increase effective sample size using appropriate statistical tools. Results: We demonstrated a beneficial effect of empirically given low-dose metronomic chemotherapy (HR 0.46 for relapses, p = 0.017) as well as various repurposed or targeted agents (HR 0.15 for deaths, p = 0.004) in a real-life scenario. However, targeted agents given on the basis of limited biological information were not beneficial. Conclusions: Comparative patient series analysis provides institutional-level evidence for treatment individualization in high-risk pediatric malignancies. Our findings emphasize the need for a comprehensive, multi omics assessment of the tumor and the host as well whenever molecularly driven targeted therapies are being considered. Low-dose metronomic chemotherapy or local control of the disease may be a more rational option in situations where targeted treatment cannot be justified by robust evidence and comprehensive biological information. "Targeted drugs" may be given empirically with a realistic benefit expectation when based on robust rationale.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Polaskova, Kristyna $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Kuttnerova, Zuzana $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Merta, Tomas $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Neradil, Jakub $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia. Laboratory of Tumor Biology, Department of Experimental Biology, School of Science, Masaryk University, Brno, Czechia.
700    1_
$a Berkovcova, Jitka $u Laboratory of Molecular Pathology, Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czechia.
700    1_
$a Horky, Ondrej $u Laboratory of Molecular Pathology, Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czechia.
700    1_
$a Jezova, Marta $u Department of Pathology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Veselska, Renata $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia. Laboratory of Tumor Biology, Department of Experimental Biology, School of Science, Masaryk University, Brno, Czechia.
700    1_
$a Klement, Giannoula Lakka $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. CSTS Health Care Inc., Toronto, ON, Canada.
700    1_
$a Valik, Dalibor $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czechia.
700    1_
$a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czechia.
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 9, č. - (2019), s. 644
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31380281 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011115347 $b ABA008
999    __
$a ind $b bmc $g 1452507 $s 1074397
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c - $d 644 $e 20190717 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
GRA    __
$a NV16-33209A $a NV16-34083A $p MZ0 $p MZ0
GRA    __
$a NV16-33209A $a NV16-34083A $p MZ0 $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace